Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variations in HMGCR and PCSK9 and kidney function: a Mendelian randomization study

22 May 2023

Abstract excerpt

BACKGROUND: The genetically predicted lipid-lowering effect of HMGCR or PCSK9 variant can be used to assess drug proxy effects on kidney function. METHODS: Mendelian randomization (MR) analysis-identified HMGCR and PCSK9 genetic variants were used to predict the low-density lipoprotein (LDL) cholesterol-lowering effects of medications targeting related molecules. Primary summary-level outcome data for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Kidney Disease and Diabetes
Share to Genetic Associations and Epidemiology
Share to Lipoproteins and Cardiovascular Health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37448291
DOI: 10.23876/j.krcp.22.237

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variations in HMGCR and PCSK9 and kidney function: a Mendelian randomization studyPMID 37448291Read ↗

Lipid-lowering drugs and risk of rapid renal function decline: a mendelian randomization study.Semantic proximity Read ↗

Lipid-Lowering Drugs and Risk of Rapid Renal Function Decline: A Mendelian Randomization StudySemantic proximity Read ↗

Effects of genetically proxied statins on diabetic nephropathy and retinopathy: a Mendelian randomization study.Semantic proximity Read ↗

Genetic association analysis of lipid-lowering drug target genes in chronic kidney disease.Semantic proximity Read ↗

Genetically instrumented LDL-cholesterol lowering and multiple disease outcomes: A Mendelian randomization phenome-wide association study in the UK Biobank.Semantic proximity Read ↗

Blood lipid genetic scores, the HMGCR gene and cancer risk: a Mendelian randomization study.Semantic proximity Read ↗

Mendelian Randomization Reveals the Role of HMGCR in Pulmonary Arterial Hypertension Treatment, Independent of LDL Cholesterol ConcentrationSemantic proximity Read ↗

The causal effects of serum lipids and apolipoproteins on kidney function: multivariable and bidirectional Mendelian-randomization analysesSemantic proximity Read ↗

Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four AncestriesSemantic proximity Read ↗

A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes.Semantic proximity Read ↗

Cardiometabolic drugs and kidney function – a drug target Mendelian randomisation studySemantic proximity Read ↗

Associations of Lipid-Lowering Drugs With Blood Pressure and Fasting Glucose: A Mendelian Randomization Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.